Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
about
Paget's disease of bone: an osteoimmunological disorder?Update on biomarkers in systemic sclerosis: tools for diagnosis and treatmentProinflammatory effects of diesel exhaust nanoparticles on scleroderma skin cellsHeart diastolic dysfunction in patients with systemic sclerosis.Role of Plasma MMP 9 levels in the Pathogenesis of Chronic Pancreatitis.Application of biomarkers to clinical trials in systemic sclerosis.Effects of streptolysin o on extracellular matrix gene expression in normal human epidermal keratinocytes.Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure.Cholinergic Stimulation Prevents the Development of Autoimmune Diabetes: Evidence for the Modulation of Th17 Effector Cells via an IFNγ-Dependent Mechanism.B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosisBiomarkers for skin involvement and fibrotic activity in scleroderma.Serum levels of matrix metalloproteinases: implications in clinical neurology.Matrix metalloproteinases: a review of their structure and role in systemic sclerosis.Circulating biomarkers of interstitial lung disease in systemic sclerosis.Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease.Transforming growth factor β--at the centre of systemic sclerosis.Facts and promises on lung biomarkers in interstitial lung diseases.Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis.Clinical significance of serum soluble Tie1 levels in patients with systemic sclerosis.The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis.Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis.Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients.Upregulated expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in BALB/c mouse brain challenged with Japanese encephalitis virus.Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement.Sensitivity of serum concentration of cartilage biomarkers to 21-days of bed rest.Ability of trichloroethylene metabolite to promote immune pathology is strain-specific.Evaluation of the Anterior Segment Parameters of the Patients with Scleroderma.
P2860
Q26796458-AF9A8B5F-4084-4827-AD53-031B98933375Q26995542-74075B42-5582-4D9F-BFC5-09BED75B094AQ28658168-0A757283-F4F8-43C9-B8BB-E0E72EE6BE02Q33935334-79CD6BFA-C757-4573-A5E1-2F97C70D0A48Q35022405-E2356D3B-F42E-4EE3-A257-91D7602C56FFQ35681874-D4997A3A-72CE-4813-A067-57D7C05FB955Q35860228-063C4547-572A-4B33-883E-4D624843D58EQ37071471-7B3B7C27-B31B-41C5-8A4F-A5FC155917D5Q37335056-B7D774FE-7230-4D71-83E7-C4A0390FAF07Q37690672-2A90656D-0B43-4F2F-AC77-F3FB142E5568Q37912251-3C50E808-A5C5-4827-B934-0B8B0ECF9F83Q37977361-824F36E9-913B-49B6-8CC0-3A5F1703EA09Q38024303-FF8958DD-4B2A-4A73-AFF3-A5A70ED62FFFQ38044387-E9C0CBF2-E9A2-449C-B289-9CFD40330E1BQ38156227-D148F3E4-C9D1-4AB4-884B-E357CCA4BC82Q38204104-7D892F12-58F4-4407-B09B-4A6979B0682EQ38241227-C43A94BB-D6FA-413F-9B8B-90F884FFEFD1Q38543042-913245A2-545E-46E2-AB73-4B68C865A3E9Q38670015-15D67393-7740-4860-BAE7-4B44EAD3D58BQ38771824-F3FE588A-63A0-483F-AE36-D650896546D7Q38930001-EEF864B3-1007-46B5-A29A-63BE08E3554DQ40079788-B115C967-E402-4F70-BA82-970B15ED4859Q40099352-65809DA3-D7BE-403E-8201-47529842AA80Q40154356-807C781D-0765-4688-8C5A-F97182EB4ED3Q40289594-6F7F5B60-2A5C-4EF7-873C-6ED00BA990CAQ42978654-13AFEE42-B3C1-4B04-91DA-1295D4AF6F01Q43983260-8E19508F-DF6D-40E2-A93A-CA532C8FBC37Q46128502-E136C00E-CAC2-4B29-AB56-89402F4357C1Q46287411-D8E650C6-22E9-4CE3-9CE7-32F1D3F63157Q47596401-966E8EBC-BB51-44B8-9BB2-1AE1F17380C7
P2860
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
@ast
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
@en
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
@nl
type
label
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
@ast
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
@en
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
@nl
prefLabel
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
@ast
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
@en
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
@nl
P2093
P2860
P356
P1476
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
@en
P2093
Chul-Soo Cho
Kyung-Hee Hong
So-Youn Min
Sung-Hwan Park
Wan-Uk Kim
Yong-Joo Shin
P2860
P2888
P356
10.1186/AR1454
P407
P577
2005-01-01T00:00:00Z